RxDoctor Payments Data

Yared Gebreyesus, MD

Internal Medicine · Stafford, VANPI 1366432692

Payments from drug & device makers

$1,327in general payments, 2019–2025

Across 72 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$491
  • Amgen$173
  • Merck$104
  • GSK$98
  • Exact Sciences$96
  • Novartis$93
  • plus $271 from 10 others

What the payments were for

  • Food & beverage$1,31199%
  • Entertainment$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,327 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$148,496
Medicare patients
462
Services billed
1,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$125,785
EliquisApixaban73$95,153
JanuviaSitagliptin Phosphate35$52,142
TrulicityDulaglutide50$51,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$37,938
JardianceEmpagliflozin30$35,221
MounjaroTirzepatide23$27,521
TradjentaLinagliptin12$14,410
Tresiba Flextouch U-100Insulin Degludec13$9,564
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$7,628
Tresiba Flextouch U-200Insulin Degludec11$7,439
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$5,215
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp13$4,256
Humalog Kwikpen U-100Insulin Lispro19$4,079
Albuterol Sulfate HfaAlbuterol Sulfate162$3,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$491$125,78593 claims
PfizerEliquis$75$95,15373 claims
Lilly USA, LLCTrulicity, Mounjaro$36$78,81473 claims
MerckJanuvia$104$52,14235 claims
GSKTrelegy Ellipta$98$37,93841 claims
AbbVieSynthroid$28$78614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Stafford

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →